Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come

Lung cancer is the leading cause of cancer mortality. Great advances in non-small cell lung cancer therapy have been seen in the last decade, beginning with the success in treating lung cancer harboring EGFR mutations and ALK-gene rearrangements. The potential of these biomarker-driven therapies has...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Crit Rev Oncog
Autori principali: Garon, Edward B., Abarca, Phillip A., Strunck, Jennifer L., Nameth, Danielle, Neumann, Catherine, Wolf, Brian, Kim, Kevin Y., Marx, Caitlin, Elashoff, Robert M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5273860/
https://ncbi.nlm.nih.gov/pubmed/27279233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1615/CritRevOncog.v20.i5-6.70
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi